Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1

The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+ET in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Toi, Masakazu, Boyle, Frances, Im, Young-Hyuck, Reinisch, Mattea, Molthrop, David, Jiang, Zefei, Wei, Ran, Sapunar, Francisco, Grimes, Brenda R, Nabinger, Sarah Cassidy, Johnston, Stephen R D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847542/
https://www.ncbi.nlm.nih.gov/pubmed/36342342
http://dx.doi.org/10.1093/oncolo/oyac234
Descripción
Sumario:The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+ET in patients with HR+, HER2− early breast cancer at high risk of recurrence (ClinicalTrials.gov: NCT03155997 [monarchE]).

Ejemplares similares